Taken together, EMT-TFs can augment the activity of ABC transporters in various breast cancer cell lines by directly binding to their promoters, thereby leading to enhanced drug efflux, which constitutes a pivotal molecular mechanism of EMT-induced drug resistance. This evidence concerns the gene ABCG2 and breast carcinoma.